Deborah Raymond
Overview
Explore the profile of Deborah Raymond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ortega R, Bodamer O, Peake R, Raymond D, Bressman S, Saunders-Pullman R
Mov Disord
. 2022 Feb;
37(3):655-656.
PMID: 35106836
No abstract available.
12.
Navarro E, Udine E, de Paiva Lopes K, Parks M, Riboldi G, Schilder B, et al.
Nat Aging
. 2022 Jan;
1(9):850-863.
PMID: 35005630
An increasing number of identified Parkinson's disease (PD) risk loci contain genes highly expressed in innate immune cells, yet their role in pathology is not understood. We hypothesize that PD...
13.
Cubo E, Miravite J, Calvo S, Cooper K, Raymond D, Ooi H, et al.
Parkinsonism Relat Disord
. 2021 Dec;
93:85-88.
PMID: 34856447
Background: The minimal clinically important difference (MCID) describes the smallest change in an outcome that is considered clinically meaningful. The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) is the most frequently rating...
14.
Leaver K, Viser A, Kopell B, Ortega R, Miravite J, Okun M, et al.
J Neurosurg
. 2021 Nov;
137(1):184-191.
PMID: 34798606
Objective: The objective of this study was to evaluate clinical features and response to deep brain stimulation (DBS) in G2019S LRRK2-Parkinson disease (LRRK2-PD) and idiopathic PD (IPD). Methods: The authors...
15.
Xu Y, Mirelman A, Saunders-Pullman R, Mejia-Santana H, Caccappolo E, Raymond D, et al.
Clin Park Relat Disord
. 2021 Jun;
3.
PMID: 34095813
Introduction: The Montreal Cognitive Assessment (MoCA), an instrument widely used for cognitive screening in Parkinson's disease (PD), is validated in Hebrew and English. However, it remains unknown whether the scores...
16.
Lai D, Alipanahi B, Fontanillas P, Schwantes-An T, Aasly J, Alcalay R, et al.
Ann Neurol
. 2021 May;
90(1):76-88.
PMID: 33938021
Objective: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinson's disease. Methods: We performed...
17.
Ortega R, Wang C, Raymond D, Bryant N, Scherzer C, Thaler A, et al.
JAMA Netw Open
. 2021 Apr;
4(4):e215845.
PMID: 33881531
Importance: Despite a hypothesis that harboring a leucine-rich repeat kinase 2(LRRK2) G2019S variation and a glucocerebrosidase (GBA) variant would have a combined deleterious association with disease pathogenesis, milder clinical phenotypes...
18.
Moran E, Bressman S, Ortega R, Raymond D, Nichols W, Palmese C, et al.
Front Neurol
. 2021 Mar;
12:635958.
PMID: 33716938
Mutations and variants in the glucocerebrosidase () gene are among the most common genetic risk factors for the development of Parkinson's disease (PD). Yet, penetrance is markedly reduced, and less...
19.
Namnah M, Bauer M, Mor-Shaked H, Bressman S, Raymond D, Ozelius L, et al.
Mov Disord Clin Pract
. 2020 Jul;
7(5):569-570.
PMID: 32626807
No abstract available.
20.
Agalliu I, Ortega R, San Luciano M, Mirelman A, Pont-Sunyer C, Brockmann K, et al.
Mov Disord
. 2019 Jul;
34(9):1392-1398.
PMID: 31348549
Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It...